Нипертен

Quick links to important sections

Нипертен

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Нипертен

Quick Facts

Property Description
Active ingredient Bisoprolol (Бисопролол)
Form Film-coated tablet
Pharmacological class Beta-blocker (Бета-адреноблокатор)
Type Cardioselective beta1-adrenergic blocker
Origin Synthetic chemical compound
Route of administration Oral

What Type of Medicine is Нипертен?

Нипертен is a monocomponent pharmaceutical agent classified as a Beta-blocker (Бета-адреноблокатор), designed for systemic action on the cardiovascular system. It is specifically a cardioselective beta1-adrenergic blocker, meaning it primarily targets receptors located in the heart, minimizing its effect on other organs compared to non-selective agents. This category of medicine is clinically recognized for its utility in supporting a steady heart rhythm and assisting in the normalization of elevated blood pressure, providing high-level antiarrhythmic and antihypertensive support.


Bisoprolol: Composition and General Purpose

The active ingredient in Нипертен is the INN Bisoprolol (Бисопролол), a synthetic chemical compound typically supplied as Bisoprolol fumarate. This single component provides the drug's therapeutic effect. Bisoprolol is consistently recognized as an agent used in the long-term management of cardiovascular conditions. This indicates that this medicine is utilized to assist in sustained management of heart and circulatory function.

Нипертен is manufactured as a film-coated tablet for oral administration, ensuring a standardized and reliable delivery of the active substance. The drug's mechanism involves selective cardiac slowing and blood pressure modulation. Bisoprolol effectively reduces heart rate and myocardial contractility. This means that the drug helps the heart work more efficiently and lessens its mechanical demands. This fundamental action supports the heart's work and assists in the normalization of pressure within the arteries, providing antiarrhythmic, antihypertensive, and antianginal support.

Regulatory References

  1. DailyMed Drug Information (NIH)

What side effects are possible with Нипертен?

Possible side effects and safety information

The safety profile of Нипертен (Bisoprolol) is established through regulatory classifications that document adverse reactions by frequency and affected organ system, based on official prescribing information.

Documented Adverse Reactions

The most frequently observed adverse reactions are classified as Very Common or Common in regulatory documents. Bradycardia (slowed heart rate) is classified as Very Common in patients using the medication for chronic heart failure. Other Common effects, which often occur at the beginning of therapy and are generally transient, include dizziness, headache, fatigue, asthenia, and a feeling of coldness or numbness in the extremities. Gastrointestinal disturbances such as nausea, vomiting, diarrhoea, and constipation are also commonly documented.

Less frequent adverse effects, classified as Uncommon, include sleep disorders, depression, muscular weakness, cramps, and bronchospasm (in susceptible patients). Rare adverse reactions, documented as Rare or Very Rare, involve conditions such as syncope, nightmares, hallucinations, allergic rhinitis, and reactions affecting the skin, including the provocation or worsening of psoriasis.

Regulatory Safety Considerations

Official regulatory labeling highlights the potential for serious adverse reactions, primarily related to the cardiovascular system, including the risk of worsening of pre-existing heart failure and severe bradycardia. The sudden discontinuation of the medication, particularly in individuals with coronary artery disease, is officially associated with an increased risk of exacerbation of angina and serious cardiac events. The medication may also mask the symptoms of hypoglycaemia, a high-level safety constraint noted in regulatory documents.

Safety limitations apply to specific patient groups. Use is not recommended in the paediatric population due to a lack of clinical experience. Specific caution and maximum dose restrictions are required for patients with severe renal impairment or severe hepatic function disorders, as stated in official labeling.

Overdose and Emergency Response

Overdose of Нипертен (Bisoprolol) is primarily characterized by severe effects on the cardiovascular and respiratory systems, as documented in official government prescribing information. Documented physiological manifestations include marked bradycardia (excessively slow heart rate), profound hypotension (low blood pressure), and the potential for worsening of cardiac failure. Respiratory function may be compromised, presenting as bronchospasm or severe difficulty breathing.

Systemic signs such as drowsiness, confusion, weakness, and the physiological finding of hypoglycemia (low blood sugar) are also officially documented. In severe scenarios, overdose may escalate to conditions such as shock, seizures, or coma. The regulatory guidance clearly mandates that individuals must seek immediate medical attention and contact emergency services (e.g., 911 or 999) if symptoms include collapse, inability to be awakened, or severe trouble breathing.

There is no specific antidote known for Bisoprolol overdose. Therefore, treatment is explicitly defined as symptomatic and supportive. This approach involves monitoring vital signs, including performing an ECG, and providing specific pharmacological support to counteract the major physiological manifestations. Special consideration is noted for children, who are particularly susceptible to severe hypoglycemia in overdose situations.

Therapeutic Uses of Нипертен

What Нипертен Treats: Main Uses and Benefits

Нипертен (containing bisoprolol) is commonly used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed for major cardiovascular conditions. Its primary role supports the management of several chronic heart and circulatory issues, assisting with functional stability.

The medication is considered relevant for easing the overall symptom burden across conditions presenting with systemic or localized discomfort, including sustained high blood pressure (Hypertension), chronic stable chest pain (Angina Pectoris), heart failure, and irregular heart rhythms.

“The therapy is used for managing symptoms that create noticeable physiological strain and assists with maintaining functional stability when symptoms may intensify temporarily.”

In clinical settings, it is commonly used when symptoms intensify, offering symptomatic relief that helps patients cope more steadily when symptoms are more noticeable. It is relevant in contexts involving heightened systemic burden, such as complex conditions like chronic heart failure, where it assists with maintaining functional stability.


Quick Fact: Relief for Cardiovascular Strain

Symptom Type Therapeutic Goal
Elevated Blood Pressure Sustained control of pressure
Episodic Chest Discomfort Reduction in frequency and intensity
Irregular Heart Rate Assistance with maintaining stability
Chronic Cardiac Strain Support for patient's functional stability

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Нипертен (Bisoprolol) — Official Regulatory Information

Populations for whom use is allowed (as stated in label): Most adults aged 18 and over.

Populations for whom use is contraindicated: Use is strictly prohibited for patients with certain severe heart conditions, including cardiogenic shock, overt or decompensated heart failure, second or third degree AV block, and marked sinus bradycardia. Contraindication also extends to individuals with severe bronchial asthma, metabolic acidosis, or hypersensitivity to the medicine.


Age-related eligibility rules: Use is not recommended for the pediatric population (children and adolescents) as safety and efficacy have not been established. Older adults generally do not require dose adjustment unless significant liver or kidney dysfunction is present.

Condition-specific eligibility rules: Patients with severe renal impairment or severe hepatic impairment must use the medicine with caution, and a daily dose of 10 mg should not be exceeded. Caution is also advised for patients with diabetes mellitus (due to masked hypoglycemia symptoms) and bronchospastic disease.

Pregnancy and lactation eligibility status: The medicine is not recommended for use during pregnancy unless clearly necessary, nor is it recommended for mothers who are breastfeeding.


Connection to the overall eligibility profile (2 sentences): Official regulatory documents define eligibility by establishing Contraindications for severe systemic or cardiac instability, and by setting strict Restrictions for use in populations with organ impairment or in the pediatric age group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation establishes specific interaction patterns for Нипертен (Bisoprolol) based on pharmacodynamic synergy and pharmacokinetic alteration.

Contraindicated and High-Risk Combinations

Co-administration with other Beta-blocking agents is a formally prohibited combination due to the risk of additive beta-adrenergic blocking action. Caution is required when combined with drugs that depress myocardial function or AV conduction.

Interacting Class/Substance Official Interaction Outcome Classification
Other Beta-blocking agents Prohibited combination (additive effect) Contraindicated
Verapamil, Diltiazem (CCBs) Increased risk of bradycardia and hypotension Use with Caution
Antiarrhythmic agents (e.g., Disopyramide) Increased risk of bradycardia and AV block Use with Caution

Pharmacokinetic and Administration Constraints

The medicine's metabolism is not significantly affected by Cytochrome P450 II D6. However, co-administration with Rifampicin increases the metabolic clearance of Bisoprolol, resulting in a shortened elimination half-life. Pharmacokinetic studies have documented no clinically relevant interaction with Cimetidine or Warfarin.

Administration also requires a mandatory timing rule for certain substances. If combination therapy is to be discontinued, Bisoprolol must be discontinued for several days before the withdrawal of Clonidine to mitigate potential adverse events. The absorption of Bisoprolol is not affected by food intake.

Mechanism of Action

Нипертен (Bisoprolol) is a selective beta1-adrenergic receptor antagonist. Its primary biological targets are the beta1-adrenoceptors expressed predominantly on cardiac nodal tissue (sinoatrial and atrioventricular nodes) and myocytes, as well as in the juxtaglomerular cells of the kidney.

In the heart, beta1-receptor blockade competitively inhibits the binding and action of endogenous catecholamines, such as norepinephrine and epinephrine, thereby preventing the activation of the G s protein/adenylyl cyclase/cAMP signaling cascade. This intracellular modification results in a negative chronotropic effect (decreased firing rate of pacemaker cells) and a negative inotropic effect (decreased Ca^2+ influx and contractility) on the myocardium. The systemic physiological consequence is a reduction in heart rate and cardiac output.

In the kidney, antagonism of beta1-adrenoceptors on juxtaglomerular cells leads to a decrease in renin release. This action modulates the renin-angiotensin-aldosterone system cascade, leading to a subsequent reduction in the systemic concentration of angiotensin II, contributing to the overall systemic vascular and fluid status modulation.

Dosage and Administration Information

Нипертен (Bisoprolol) is a monocomponent pharmaceutical agent intended for oral administration as a film-coated tablet. The medicine is consistently administered once daily (qDay) and should be taken in the morning. Tablets can be taken with or without food, but they must always be swallowed whole with a liquid and should not be chewed or crushed.


Indication Standard Start Dose Maximum Daily Dose
Hypertension / Angina 5 mg once daily (or 2.5 mg) 20 mg
Chronic Heart Failure (CHF) 1.25 mg once daily 10 mg

For Hypertension and Angina, the usual starting dose is 5 mg once daily, progressing to a common maintenance dose of 10 mg. Treatment for Chronic Heart Failure follows a specific titration schedule, starting at 1.25 mg once daily, with the dose gradually and incrementally increased over several weeks up to the target of 10 mg. This titration phase must only be initiated when the patient is clinically stable.

Dosage constraints apply for specific populations: the dose should not exceed 10 mg daily in cases of severe renal or hepatic impairment. The drug is intended for long-term use and treatment must never be stopped abruptly; discontinuation requires a gradual reduction in dosage over approximately one to two weeks.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Нипертен

The information below summarizes the research studies that explored Нипертен (Perindopril) and what the findings describe. Research was observed in specific study populations under defined conditions; these findings describe group patterns, not personal outcomes.


Evidence for Use in High Blood Pressure (Essential Hypertension)

Research has extensively examined the use of Нипертен in adults with high blood pressure, utilizing large, controlled clinical trials. These studies monitored outcomes related to systemic or functional imbalance, specifically looking at patterns in blood pressure readings measured over defined time intervals. Trials reported measurements showing a shift in mean SBP and DBP values in the observed groups.

Data from some long-term observational studies described the patterns of blood pressure changes measured over extended follow-up periods. This research provides context but not individual predictions about the magnitude of blood pressure changes. Data on long-term outcomes related purely to blood pressure changes versus other characteristics of the compound remain limited in many observational studies.


Evidence for Cardiovascular Risk Reduction in Stable Coronary Artery Disease

Large-scale, randomized, double-blind trials have been conducted for patients who already have stable coronary artery disease (CAD), including those with a history of heart attack. The research explored outcomes related to systemic physiological strain or stress, specifically looking at a composite outcome that tracked serious events like cardiovascular death, non-fatal heart attack, and cardiac arrest. Major trials reported the absolute occurrence of these serious vascular events in the group that received the compound compared to the placebo group. The evidence does not fully characterize the changes observed over a patient's entire life span.


What Remains Unclear About Нипертен Research

The body of evidence contributes to the understanding of the compound, but several gaps exist. Very long-term changes observed are not fully established beyond the follow-up periods of the pivotal trials. Furthermore, direct comparison studies between certain combination regimens and monotherapy in secondary stroke prevention are limited. Data for certain groups, such as very advanced kidney impairment or pregnant populations, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Нипертен (FAQ)


Q: How is the mechanism of Нипертен described compared to Angiotensin Receptor Blockers (ARBs)?

Нипертен is officially classified as a beta-1 blocker. Its mechanism works by slowing the heart rate and reducing the release of the hormone renin from the kidneys. This action differs from Angiotensin Receptor Blockers (ARBs), which work by blocking the specific receptors that the hormone Angiotensin II acts upon.


Q: How quickly can a patient typically expect to see an effect after starting Нипертен?

Official product information states that the maximal effect on the heart rate can generally be observed within 1 to 4 hours after taking a single dose. This time frame indicates when the medication achieves its maximal effect on the heart rate.


Q: How long does it usually take for Нипертен to achieve its full blood pressure-lowering effect?

The full therapeutic benefit, which corresponds to the steady-state plasma level, is typically attained after about 5 days of consistent, once-daily administration. The full therapeutic effect is typically assessed after consistent use over this initial period.


Q: Is it normal not to feel any immediate change or symptom relief when taking Нипертен for hypertension?

Yes, it is normal not to feel a change. The medicine works internally to manage blood pressure and heart function, conditions that are often asymptomatic. Therefore, the presence or absence of an immediate sensation is not typically used as an indicator of the medication’s effectiveness.


Q: Is a persistent dry cough a commonly reported side effect of Нипертен?

According to official product monographs, coughing is listed as a possible adverse experience. However, regulatory documents do not consistently classify it among the Very Common or Common side effects for all patient groups.


Q: How should dizziness or lightheadedness upon standing from Нипертен be managed?

Dizziness and lightheadedness, particularly when changing position (known as orthostatic hypotension), is a reported effect. Official information describes that caution is recommended when changing position. If this effect is severe or persistent, it is listed as a symptom that should be addressed by a healthcare professional.


Q: What are the possible signs of low blood pressure (hypotension) that may occur with Нипертен?

Signs of low blood pressure that may occur include a feeling of lightheadedness, dizziness, or fainting. These symptoms are often most noticeable when a person moves quickly from a sitting or lying position to standing.


Q: Is a mild skin rash a temporary side effect that can occur with Нипертен?

Skin reactions, including a rash and itching, are listed in official documents as a Rare adverse event. Regulatory documents state that severe skin reactions require immediate medical attention.


Q: What are the documented effects of Нипертен on sexual health or function?

Official product information documents list changes in sex drive or performance as reported adverse experiences. Impotence is also documented as a possible side effect.


Q: How is the rare but serious side effect called angioedema described in relation to Нипертен?

Official warnings address the potential for severe allergic reactions. Symptoms described in regulatory documents include the rapid swelling of the mouth, face, lips, tongue, or throat. These reactions require immediate medical help.


Q: What is the risk of developing high potassium levels (hyperkalemia) while on Нипертен?

Нипертен is a cardioselective agent. While it carries a lower potential risk for high potassium levels (known as hyperkalemia) compared to certain other blood pressure medications, the compound is associated with cautions regarding concurrent medications that affect potassium levels. This often necessitates medical oversight.


Q: What specific symptoms should prompt a person to seek immediate medical attention while taking Нипертен?

Official documents specify that immediate medical help is required for symptoms like swelling of the face, lips, tongue, or throat, which may indicate a severe allergic reaction. Other critical symptoms include difficulty breathing or wheezing, and episodes of severe dizziness or fainting.


Q: Is the regular monitoring of blood test results required during long-term treatment with Нипертен?

Yes, regulatory guidance stresses the need for regular visits and monitoring by a doctor while taking this medication. The purpose of this monitoring is to check for potential unwanted effects, which may include laboratory testing.


Q: How is the initial, small decrease in kidney function (eGFR) explained when starting an ACE inhibitor like Нипертен?

The mechanism of Bisoprolol includes reducing the release of renin by the kidneys, which is a key component of the system that regulates blood pressure. While the official documents address dosing constraints for severe kidney impairment (not exceeding 10 mg daily), the medication is generally not expected to require adjustment for milder forms of kidney impairment.


Q: Are there any known safety considerations regarding the consumption of alcohol while taking Нипертен?

Official warnings indicate that alcohol may have an additive effect in lowering blood pressure. This combination can result in an increased risk of dizziness, lightheadedness, fainting, or a marked change in heart rate.


Q: Can common over-the-counter pain relievers, like NSAIDs, interact with Нипертен?

Yes, information from regulatory documents indicates that Non-steroidal Anti-inflammatory Drugs (NSAIDs), a common class of pain reliever, may cause an interaction. This interaction may result in a reduction of the medication’s blood pressure-lowering effect.


Q: What is the official guidance on taking cold or flu medicines while on Нипертен?

Official documentation includes a caution regarding the use of over-the-counter cough, cold, allergy, and pain medicines. Some ingredients in these products can increase blood pressure or interfere with the intended effect of the medication.


Q: Are there documented interactions between Нипертен and medications for mood or mental health?

Regulatory documents mention that co-administration with certain medications, such as tricyclic antidepressants, can increase the risk of hypotension (low blood pressure). This general warning applies to any drug that has the potential to lower blood pressure when combined with Нипертен.


Q: Can Нипертен be safely combined with diuretics (water pills) for blood pressure control?

Yes, the medication is often included in treatment regimens that also involve diuretics (commonly known as water pills). Regulatory documents confirm that combination therapy with diuretics is part of the standard management for conditions such as hypertension and chronic heart failure.


Q: Are there any special considerations for using Нипертен before having surgery or receiving general anesthesia?

Official warnings state that the anaesthetist is typically informed about the use of this medication prior to receiving surgery or general anesthesia. This is due to the potential for drug interactions and the risk of bradyarrhythmias (slow heart rate) or reduced heart rate response during the procedure.


Q: What is the recommended procedure if a person forgets to take a dose of Нипертен?

The recommended procedure is to take the missed dose as soon as it is remembered on the same day. If the dose is not remembered until the next day, the missed dose should be skipped entirely, and the regular schedule should be resumed. It is specified that a person should never take two doses to make up for a missed one.


Q: Are there specific pre-existing health conditions, like severe kidney or liver disease, that prohibit the use of Нипертен?

Yes, official documents specify certain conditions that prohibit use, such as cardiogenic shock or second/third degree AV block. Conditions like severe renal or hepatic impairment do not prohibit use entirely but require specific caution and may necessitate a restricted maximum daily dose of 10 mg.

How should Нипертен be stored and disposed of?

How to Store and Dispose of Нипертен?

Нипертен (Bisoprolol) must be stored and disposed of according to official regulatory guidelines to maintain its effectiveness and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store below 25°C (or 30 C) at Controlled Room Temperature.
Protection Keep in the original package to protect from light and moisture.
Child Safety Store out of the sight and reach of children.

Stability and Disposal

The medicine must not be refrigerated or frozen. If supplied in a bottle, the stability period after the first opening is typically 6 months. Unused or expired tablets and any waste material must be disposed of in accordance with local requirements for pharmaceutical waste, ensuring they are not discharged into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Нипертен found in:

A-Z Index: